Alison Freimund

547 total citations
11 papers, 375 citations indexed

About

Alison Freimund is a scholar working on Oncology, Reproductive Medicine and Genetics. According to data from OpenAlex, Alison Freimund has authored 11 papers receiving a total of 375 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Reproductive Medicine and 3 papers in Genetics. Recurrent topics in Alison Freimund's work include PARP inhibition in cancer therapy (7 papers), Ovarian cancer diagnosis and treatment (4 papers) and BRCA gene mutations in cancer (3 papers). Alison Freimund is often cited by papers focused on PARP inhibition in cancer therapy (7 papers), Ovarian cancer diagnosis and treatment (4 papers) and BRCA gene mutations in cancer (3 papers). Alison Freimund collaborates with scholars based in Australia, China and United Kingdom. Alison Freimund's co-authors include David D.L. Bowtell, Jessica A. Beach, Elizabeth L. Christie, Linda Mileshkin, Virginia Paton, Tarek Meniawy, Michael Millward, Joanne Lundy, Ben Markman and Paul R. Harnett and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Alison Freimund

11 papers receiving 375 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alison Freimund Australia	8	276	139	126	57	50	11	375
Valerie Bowering Canada	10	310 1.1×	168 1.2×	176 1.4×	51 0.9×	37 0.7×	28	378
Philip Rowe United Kingdom	6	328 1.2×	152 1.1×	201 1.6×	39 0.7×	44 0.9×	7	389
Tabari M. Baker United States	6	265 1.0×	234 1.7×	40 0.3×	33 0.6×	98 2.0×	12	406
Laura Barker United Kingdom	8	330 1.2×	152 1.1×	159 1.3×	48 0.8×	71 1.4×	17	478
Perrine Garde‐Granger Canada	11	166 0.6×	125 0.9×	117 0.9×	117 2.1×	52 1.0×	12	349
Floriana Camarda Italy	7	136 0.5×	89 0.6×	48 0.4×	18 0.3×	44 0.9×	27	236
Shamima Yeasmin Japan	10	115 0.4×	289 2.1×	94 0.7×	24 0.4×	123 2.5×	19	442
Nicholas Badham United Kingdom	2	185 0.7×	271 1.9×	37 0.3×	22 0.4×	46 0.9×	2	328
Jinxiao Liang China	10	83 0.3×	218 1.6×	35 0.3×	39 0.7×	100 2.0×	27	330
Valerie Heong Singapore	10	135 0.5×	107 0.8×	74 0.6×	52 0.9×	48 1.0×	25	243

Countries citing papers authored by Alison Freimund

Since Specialization

Citations

This map shows the geographic impact of Alison Freimund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Freimund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Freimund more than expected).

Fields of papers citing papers by Alison Freimund

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Freimund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Freimund. The network helps show where Alison Freimund may publish in the future.

Co-authorship network of co-authors of Alison Freimund

This figure shows the co-authorship network connecting the top 25 collaborators of Alison Freimund. A scholar is included among the top collaborators of Alison Freimund based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Freimund. Alison Freimund is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Frenel, Jean‐Sébastien, Rebecca Asher, Dominique Berton, et al.. (2022). Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Annals of Oncology. 33(10). 1021–1028. 81 indexed citations

Edbrooke, Lara, Pearly Khaw, Alison Freimund, et al.. (2022). ENhAncing Lifestyle Behaviors in EndometriaL CancEr (ENABLE): A Pilot Randomized Controlled Trial. Integrative Cancer Therapies. 21. 1543385021–1543385021. 8 indexed citations

Freimund, Alison, Kortnye Smith, Rodney J. Hicks, et al.. (2021). Cancer Diagnoses Following Abnormal Noninvasive Prenatal Testing: A Case Series, Literature Review, and Proposed Management Model. JCO Precision Oncology. 5(5). 1001–1012. 22 indexed citations

Frenel, Jean‐Sébastien, JW Kim, Dominique Berton-Rigaud, et al.. (2020). 813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial. Annals of Oncology. 31. S615–S615. 16 indexed citations

Frenel, Jean‐Sébastien, Jae‐Weon Kim, Dominique Berton, et al.. (2020). Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353).. Journal of Clinical Oncology. 38(15_suppl). 6070–6070. 3 indexed citations

Friedländer, Michael, Tarek Meniawy, Ben Markman, et al.. (2019). Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. The Lancet Oncology. 20(9). 1306–1315. 89 indexed citations

Mileshkin, Linda, Dariush Etemadmoghadam, Richard W. Tothill, et al.. (2019). Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective study: Experience of the first two years.. Journal of Clinical Oncology. 37(15_suppl). 3072–3072. 4 indexed citations

Freimund, Alison, Jessica A. Beach, Elizabeth L. Christie, & David D.L. Bowtell. (2018). Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer. Hematology/Oncology Clinics of North America. 32(6). 983–996. 90 indexed citations

Friedländer, Michael, Tarek Meniawy, Ben Markman, et al.. (2018). A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.. Journal of Clinical Oncology. 36(5_suppl). 48–48. 31 indexed citations

10.

Lickliter, Jason D., Linda Mileshkin, Mark Voskoboynik, et al.. (2017). Dose escalation/expansion study to investigate the safety, pharmacokinetics, food effect, and antitumor activity of BGB-290 in patients with advanced solid tumors. Annals of Oncology. 28. v123–v123. 6 indexed citations

11.

Friedländer, Michael, Tarek Meniawy, Ben Markman, et al.. (2017). A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 3013–3013. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact